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doi:10.1016/j.jtcvs.2003.11.052In this issue of the Journal, Battafarano and colleagues1 report their expe-rience with resection of malignant lung tumors in 69 patients who hadpreviously undergone resection of a malignant lung tumor. On the basis ofa retrospective analysis, they found that resection of so-called metachro-nous lung tumors could be performed in selected patients with an accept-able surgical mortality rate (5.8%) and meaningful long-term survival
(5-year survival of 33.4%). The authors note that the 5-year actuarial survival of
patients who had metachronous stage I non–small cell lung cancer (NSCLC)
resected was significantly longer than that in patients with more advanced meta-
chronous lesions (42% vs 10%, P  .01). Most of the patients underwent anatomic
resection of their metachronous lung tumors, but 42% underwent wedge resection,
presumably because of limited pulmonary function. No mention was made of how
these metachronous tumors were detected, whether through surveillance in other-
wise asymptomatic patients or as a result of the evaluation of patients with
symptoms or signs of recurrence. Given these findings, this article raises a number
of questions about the clinical management of patients with a history of resected
lung cancer who present with a new lung mass. Because patients with earlier stage
metachronous tumors survived longer, the article also raises questions about the
optimum follow-up of patients after potentially curative resection for lung cancer.
The authors point out that one major problem faced by the clinician is the
differentiation of metachronous lung cancer from recurrent-metastatic lung cancer.
Battafarano and colleagues1 used the criteria proposed by Martini and Melamed2 in
1975 to define a metachronous tumor as a second primary lung cancer (Table 1).
Clinicians realize that misclassification of a metachronous tumor as a metastasis
rather than a second primary lung cancer and vice versa still occurs, even if these
criteria are followed. Despite this, the criteria of Martini and Melamed are generally
accepted3-5 or applied with modifications.6,7 Perhaps the specific criterion that is
most commonly questioned is that a metachronous tumor of the same histologic type
as the patient’s first tumor should be considered a second primary tumor if it
appeared at least 2 years after the diagnosis of the original lung cancer. In 1995,
Martini and associates8 presented data from 598 patients who underwent complete
resection of stage I NSCLC that showed that most (60%) lung cancer recurrences in
this group occurred within the first 2 years. However, in a series of 90 patients
undergoing resection of second and third primary cancers, Mathisen and coworkers9
found that there was a significant difference in survival of patients with second
primary cancers who presented more than 3 years after treatment of the initial
primary cancer. This suggests that a number of patients presenting with metachro-
nous tumors between 2 and 3 years after their original tumor actually have meta-
static disease and not a second primary cancer (or possibly that some second
primary cancers develop more slowly and have a better prognosis). Perhaps to avoid
this controversy, the investigators who designed the National Cancer Institute
Intergroup Trial (NCI#I91-0001), which demonstrated the inability of isotretinoin to
prevent second primary tumors in patients after resection of stage I NSCLC,
originally defined second primary lung cancers as those occurring 5 years after the
original cancer was treated if the same histology was present in both tumors.10
Interestingly, Battafarano and colleagues1 found no difference in survival of their
patients on the basis of a comparison of those presenting with a metachronous tumor





Lin the first 2 years after their original operation versus those
who presented with a metachronous tumor after 2 years.
Although it seems clear that the longer the time interval
from the primary cancer and its treatment the more likely it
is that one is treating a second primary cancer, the specific
time interval used as a criterion remains in question. Nev-
ertheless, the length of time before presentation with a
metachronous tumor when the histologic type is the same as
that of the initial lung tumor remains an important criterion
until a better one is found. Molecular biology will ultimately
yield the best method for distinguishing recurrence-metas-
tasis from second primary cancer. Investigators have eval-
uated small series of patients using DNA ploidy analysis11
and analysis of chromosome deletion patterns12 with some
utility. However, the development of reliable and practical
molecular biologic definitions requires prospective evalua-
tion of tissue from greater numbers of patients with meta-
chronous tumors. Finally, what also seems clear is that more
data are required on the natural history of recurrence in the
current era of treatment, in which patients receive multimo-
dality treatments or adjuvant therapy or are enrolled in
clinical trials of sublobar resection, radiofrequency ablation,
or brachytherapy.
When a metachronous tumor is detected, how should it
be treated? A careful staging evaluation should be per-
formed to rule out extrathoracic sites of tumor. In the series
presented by Battafarano and colleagues,1 anatomic resec-
tion was possible; however, 42% of patients were treated
with wedge resection because of limited pulmonary func-
tion in these patients who had undergone one prior pulmo-
nary resection. Additionally, the authors point out that their
series represents 3% of all of the patients at their institution
undergoing surgical intervention for NSCLC over a period
of 14 years. Furthermore, they speculate that this probably
underestimates the true incidence of metachronous tumors
because their surgical database included only patients with
sufficient lung function to undergo an operation. This points
out the problem of limited lung function in treating this
particular group of patients. As experience grows with cur-
rently novel therapies, such as radiofrequency ablation and
stereotactic radiation therapy, these modalities might find
TABLE 1. Criteria for diagnosis
Metachronous tumors
A. Histology different
B. Histology the same if:
1. free interval between cancers of at least 2 y or
2. origin from carcinoma in situ or
3. second cancer in different lobe or lung but
a. no carcinoma in lymphatics common to both
b. no extrapulmonary metastasis at time of diagnosis
Adapted from Martini and Melamed.2application in the treatment of patients with metachronous
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nous tumors might lead to an increase in the number of
patients with these tumors who receive potentially curative
therapy despite having limited pulmonary function.
How then should patients be followed after resection of
early stage NSCLC? As mentioned earlier, Battafarano and
colleagues1 found that the stage of the metachronous tumor
correlated significantly with survival. This finding suggests
that there might be a benefit to systematic postoperative
surveillance of patients after resection, with the goal of
detecting metachronous tumors at the earliest possible
stage. The data in the current report are similar to data
recently published by Rice and associates.13 They reported
data from patients enrolled in the National Cancer Institute
Chemoprevention Trial who had second primary lung can-
cers after resection of pathologic stage I NSCLC.10 Patients
were followed with clinical examinations and semiannual
chest radiographs. They found that the median survival of
patients who were able to undergo resection of their meta-
chronous tumor (4.1 years) was significantly longer that that
for those who could not undergo resection because their
metachronous tumors were detected at a more advanced
stage (1.4 years, P  .003), again suggesting that surveil-
lance might benefit patients through detection of resectable
metachronous tumors. Rice and associates13 noted that de-
spite semiannual chest radiography, 24% of the patients
already had metastatic disease at the time of the diagnosis of
their second primary lung cancer. Would chest computed
tomography (CT) perform better? Chiu and coworkers14
recently reported that regular prospective follow-up of 43
patients after complete resection of NSCLC with low-dose
helical CT detected significantly more recurrences than
chest radiography alone, with most patients being asymp-
tomatic at the time the recurrence was detected. This is not
surprising given the information from lung cancer screening
studies with low-dose helical CT in comparison with the
plain chest radiograph.15 After complete resections for stage
I NSCLC, patients develop second primary cancers at a rate
of 2% per patient per year.13 After 5 years, that patient has
a 10% chance of having a second primary lung cancer.
Because clinical data show that postresection patients are at
greater risk than any other group for development of a new
(in this case, second) lung cancer, surveillance with low-
dose spiral CT would seem to be of great potential benefit in
this group. However, just as screening for initial lung cancer
in high-risk individuals is controversial, so too is surveil-
lance (ie, screening) for second primary lung cancers in
individuals who have already had an initial lung cancer
resected and for the same reasons: the biases associated with
screening and the potential to cause harm with false-positive
diagnoses.16 Only a randomized clinical trial of sufficient
power could detect a true benefit in terms of mortality from








Lunderway is just such a trial, albeit in patients who have not
been previously treated for lung cancer. However, the re-
sults of this study are many years away.
Should we then agree with the experts who point out that
postoperative surveillance is currently of no proven value
and that unless a randomized controlled trial can be
mounted, there is no reason to do more than what we do
now: follow our patients on the basis of our own biases,
with some surgeons obtaining chest radiographs, some ob-
taining CT scans, and some performing periodic physical
examinations only until symptoms develop? I would pro-
pose instead that the thoracic surgical community attempt to
answer the questions raised by articles such as the one by
Battafarano and colleagues,1 if not through a randomized
trial (as seems unlikely), then through a large, prospective,
multicenter study with standardized means of follow-up,
such as periodic, low-dose helical CT. The goals would be
to determine the performance characteristics of low-dose
helical CT in the postresection setting (pneumonectomy,
lobectomy, segmentectomy, or wedge resection) and to
determine the natural history of metachronous lung cancer
in the current era given better staging and especially newer
treatments, such as sublobar resections for small cancers.
Although the detection of second primary lung cancers is
important, the early detection of local recurrence has not
been shown to be of much value because in most cases
treatment is less than effective. However, single institutions
have recently reported their experiences with sublobar re-
sections for the treatment of selected patients with stage I
NSCLC, and phase II clinical trials are being designed.17
Previous data suggest that sublobar resections alone are
associated with a higher rate of local recurrence.18 A local
recurrence after sublobar resection of a small peripheral
tumor would likely be treatable by anatomic reresection or
other means if detected early through routine surveillance,
providing yet another reason to prospectively evaluate more
effective methods of postoperative surveillance than the
plain chest radiograph. A clinical trial of postoperative
surveillance with low-dose helical CT should include a
tissue bank of resected specimens, both initial cancers and
metachronous tumors, enabling molecular biologists to
work on better definitions of second primary tumors. This
would also benefit patients presenting with synchronous
lung tumors. And of course we should continue to support
chemoprevention trials for this group of patients, such as the
Intergroup Selenium Chemoprevention Trial (ECOG 5597).
The Journal of ThoraciIf we choose not to do these things, then in 5 years, when
another author writes about metachronous lung cancer, that
editorial is likely to seem very similar to this one.
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